Common Contracts

379 similar Open Market Sale Agreement contracts by ACELYRIN, Inc., Achieve Life Sciences, Inc., Aehr Test Systems, others

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • June 5th, 2025 • LIGHTBRIDGE Corp • Services-management consulting services • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • May 30th, 2025 • Rigetti Computing, Inc. • Services-computer programming services • New York

Rigetti Computing, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $350,000,000 on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM1
Open Market Sale Agreement • May 8th, 2025 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • April 1st, 2025 • Boundless Bio, Inc. • Pharmaceutical preparations • New York
Contract
Open Market Sale Agreement • March 31st, 2025 • Instil Bio, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 28th, 2025 • CG Oncology, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSM1
Open Market Sale Agreement • March 27th, 2025 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

Kyverna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 20th, 2025 • Navitas Semiconductor Corp • Semiconductors & related devices • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 19th, 2025 • Jasper Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 18th, 2025 • Milestone Pharmaceuticals Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 17th, 2025 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • New York

Metagenomi, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 13th, 2025 • Berry Corp (Bry) • Crude petroleum & natural gas • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 11th, 2025 • Mural Oncology PLC • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 6th, 2025 • Nuvation Bio Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 4th, 2025 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • March 3rd, 2025 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • February 27th, 2025 • Cytokinetics Inc • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • February 3rd, 2025 • ArriVent BioPharma, Inc. • Pharmaceutical preparations • New York

ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to the Maximum Program Amount (as defined below) on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • January 27th, 2025 • Capital Clean Energy Carriers Corp. • Deep sea foreign transportation of freight • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • December 23rd, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT1
Open Market Sale Agreement • December 20th, 2024 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • New York
JEFFERIES LLC
Open Market Sale Agreement • December 20th, 2024 • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • December 20th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 27th, 2024 • Gyre Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 13th, 2024 • Palladyne AI Corp. • Services-prepackaged software • New York

Palladyne AI Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 13th, 2024 • ACELYRIN, Inc. • Pharmaceutical preparations • New York
AMENDED AND RESTATED OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 7th, 2024 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 7th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • November 7th, 2024 • Virgin Galactic Holdings, Inc • Transportation services • New York

Virgin Galactic Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $300,000,000 on the terms set forth in this agreement (this “Agreement”).

AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • October 31st, 2024 • Travere Therapeutics, Inc. • Pharmaceutical preparations • New York

Travere Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”) on the terms set forth in this amended and restated agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENT1
Open Market Sale Agreement • October 31st, 2024 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $300,000,000 on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • October 25th, 2024 • Tiziana Life Sciences LTD • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • October 15th, 2024 • Aehr Test Systems • Instruments for meas & testing of electricity & elec signals • New York
OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • September 27th, 2024 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York

Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).

OPEN MARKET SALE AGREEMENT
Open Market Sale Agreement • September 20th, 2024 • Eledon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York